Futura Medical - Asset Resilience Ratio

Latest as of December 2020: 23.08%

Futura Medical (FUM) has an Asset Resilience Ratio of 23.08% as of December 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Futura Medical (FUM) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

GBX373.87K

≈ $45.49 USD Cash + Short-term Investments

Total Assets

GBX1.62 Million

≈ $197.12 USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2020)

This chart shows how Futura Medical's Asset Resilience Ratio has changed over time. See Futura Medical net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Futura Medical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Futura Medical (FUM) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	GBX0.00	0%
Short-term Investments	GBX373.87K	23.08%
Total Liquid Assets	GBX373.87K	23.08%

Asset Resilience Insights

Good Liquidity Position: Futura Medical maintains a healthy 23.08% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Futura Medical Industry Peers by Asset Resilience Ratio

Compare Futura Medical's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Revolution Medicines Inc NASDAQ:RVMD	Biotechnology	65.10%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Hugel Inc KQ:145020	Biotechnology	29.57%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	39.07%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	2.30%
Absci Corp NASDAQ:ABSI	Biotechnology	59.86%
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	Biotechnology	5.52%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%

Annual Asset Resilience Ratio for Futura Medical (2016–2020)

The table below shows the annual Asset Resilience Ratio data for Futura Medical.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2020-12-31	23.08%	GBX373.87K ≈ $45.49	GBX1.62 Million ≈ $197.12	+15.47pp
2019-12-31	7.61%	GBX372.90K ≈ $45.37	GBX4.90 Million ≈ $596.33	-24.12pp
2018-12-31	31.73%	GBX3.45 Million ≈ $419.94	GBX10.88 Million ≈ $1.32K	-53.58pp
2017-12-31	85.31%	GBX8.19 Million ≈ $996.95	GBX9.60 Million ≈ $1.17K	-5.51pp
2016-12-31	90.82%	GBX12.21 Million ≈ $1.49K	GBX13.44 Million ≈ $1.64K	--

pp = percentage points

About Futura Medical

LSE:FUM UK Biotechnology

Market Cap

$38.34K

GBX315.08 Million GBX

Market Cap Rank

#31462 Global

#1236 in UK

Share Price

GBX0.54

Change (1 day)

+0.37%

52-Week Range

GBX0.53 - GBX13.43

All Time High

GBX84.52